NRAS and melanoma: MIRAT, a novel cytoplasmic intergenic lncRNA, is upregulated in NRAS mutant melanoma and regulates the MEK scaffold protein IQGAP1 and MAPK signaling pathways to influence the drug resistance of tumor cells (78).